Survival benefit of metastasectomy for Krukenberg tumors from gastric cancer

Jae Ho Cheong, WooJin Hyung, Jian Chen, Junuk Kim, Seung Ho Choi, Sung Hoon Noh

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Objective. An optimal treatment strategy for ovarian metastases of gastric cancer has not been clearly established. The aim of this study was to examine the role of a metastasectomy in the management of metachronous Krukenberg tumors after curative surgery for gastric cancer. Methods. Among 1235 female patients who had undergone a curative gastric resection for stomach cancer between 1987 and 1998, 54 (4.4%) developed Krukenberg tumors as a first recurrence without evidence of a distant metastasis. Of these 54 patients, 33 underwent a metastasectomy while 21 did not. The survival duration between the two groups was analyzed and compared. Results. The clinicopathological features of Krukenberg tumors as well as those of the primary cancers in the two groups were similar. All 33 patients in the resection group underwent subsequent adjuvant chemotherapy, including the 7 who received intraperitoneal chemotherapy. The 21 patients in the non-resection group were managed by either systemic chemotherapy (n = 16) or supportive care (n = 5) alone. The median survival duration of all the patients was 9 months (95% confidence interval, 3-15 months). The median survival time in the resection group was 17 months (95% confidence interval, 10-24 months), which was significantly longer than that in the non-resection group, 3 months (95% confidence interval, 2-4 months) (P < 0.001). Conclusion. Our results suggest that a metastasectomy was associated with an improved survival in patients with metachronous Krukenberg tumors from gastric cancer. These data offer a strong argument in favor of performing metastasectomy for Krukenberg tumors in the absence of an obvious distant metastasis.

Original languageEnglish
Pages (from-to)477-482
Number of pages6
JournalGynecologic Oncology
Volume94
Issue number2
DOIs
Publication statusPublished - 2004 Aug 1

Fingerprint

Krukenberg Tumor
Metastasectomy
Stomach Neoplasms
Survival
Confidence Intervals
Neoplasm Metastasis
Drug Therapy
Adjuvant Chemotherapy
Stomach
Recurrence

All Science Journal Classification (ASJC) codes

  • Oncology
  • Obstetrics and Gynaecology

Cite this

Cheong, Jae Ho ; Hyung, WooJin ; Chen, Jian ; Kim, Junuk ; Choi, Seung Ho ; Noh, Sung Hoon. / Survival benefit of metastasectomy for Krukenberg tumors from gastric cancer. In: Gynecologic Oncology. 2004 ; Vol. 94, No. 2. pp. 477-482.
@article{43f1b1bb5057482baa38cf46805ad7d4,
title = "Survival benefit of metastasectomy for Krukenberg tumors from gastric cancer",
abstract = "Objective. An optimal treatment strategy for ovarian metastases of gastric cancer has not been clearly established. The aim of this study was to examine the role of a metastasectomy in the management of metachronous Krukenberg tumors after curative surgery for gastric cancer. Methods. Among 1235 female patients who had undergone a curative gastric resection for stomach cancer between 1987 and 1998, 54 (4.4{\%}) developed Krukenberg tumors as a first recurrence without evidence of a distant metastasis. Of these 54 patients, 33 underwent a metastasectomy while 21 did not. The survival duration between the two groups was analyzed and compared. Results. The clinicopathological features of Krukenberg tumors as well as those of the primary cancers in the two groups were similar. All 33 patients in the resection group underwent subsequent adjuvant chemotherapy, including the 7 who received intraperitoneal chemotherapy. The 21 patients in the non-resection group were managed by either systemic chemotherapy (n = 16) or supportive care (n = 5) alone. The median survival duration of all the patients was 9 months (95{\%} confidence interval, 3-15 months). The median survival time in the resection group was 17 months (95{\%} confidence interval, 10-24 months), which was significantly longer than that in the non-resection group, 3 months (95{\%} confidence interval, 2-4 months) (P < 0.001). Conclusion. Our results suggest that a metastasectomy was associated with an improved survival in patients with metachronous Krukenberg tumors from gastric cancer. These data offer a strong argument in favor of performing metastasectomy for Krukenberg tumors in the absence of an obvious distant metastasis.",
author = "Cheong, {Jae Ho} and WooJin Hyung and Jian Chen and Junuk Kim and Choi, {Seung Ho} and Noh, {Sung Hoon}",
year = "2004",
month = "8",
day = "1",
doi = "10.1016/j.ygyno.2004.05.007",
language = "English",
volume = "94",
pages = "477--482",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "2",

}

Survival benefit of metastasectomy for Krukenberg tumors from gastric cancer. / Cheong, Jae Ho; Hyung, WooJin; Chen, Jian; Kim, Junuk; Choi, Seung Ho; Noh, Sung Hoon.

In: Gynecologic Oncology, Vol. 94, No. 2, 01.08.2004, p. 477-482.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Survival benefit of metastasectomy for Krukenberg tumors from gastric cancer

AU - Cheong, Jae Ho

AU - Hyung, WooJin

AU - Chen, Jian

AU - Kim, Junuk

AU - Choi, Seung Ho

AU - Noh, Sung Hoon

PY - 2004/8/1

Y1 - 2004/8/1

N2 - Objective. An optimal treatment strategy for ovarian metastases of gastric cancer has not been clearly established. The aim of this study was to examine the role of a metastasectomy in the management of metachronous Krukenberg tumors after curative surgery for gastric cancer. Methods. Among 1235 female patients who had undergone a curative gastric resection for stomach cancer between 1987 and 1998, 54 (4.4%) developed Krukenberg tumors as a first recurrence without evidence of a distant metastasis. Of these 54 patients, 33 underwent a metastasectomy while 21 did not. The survival duration between the two groups was analyzed and compared. Results. The clinicopathological features of Krukenberg tumors as well as those of the primary cancers in the two groups were similar. All 33 patients in the resection group underwent subsequent adjuvant chemotherapy, including the 7 who received intraperitoneal chemotherapy. The 21 patients in the non-resection group were managed by either systemic chemotherapy (n = 16) or supportive care (n = 5) alone. The median survival duration of all the patients was 9 months (95% confidence interval, 3-15 months). The median survival time in the resection group was 17 months (95% confidence interval, 10-24 months), which was significantly longer than that in the non-resection group, 3 months (95% confidence interval, 2-4 months) (P < 0.001). Conclusion. Our results suggest that a metastasectomy was associated with an improved survival in patients with metachronous Krukenberg tumors from gastric cancer. These data offer a strong argument in favor of performing metastasectomy for Krukenberg tumors in the absence of an obvious distant metastasis.

AB - Objective. An optimal treatment strategy for ovarian metastases of gastric cancer has not been clearly established. The aim of this study was to examine the role of a metastasectomy in the management of metachronous Krukenberg tumors after curative surgery for gastric cancer. Methods. Among 1235 female patients who had undergone a curative gastric resection for stomach cancer between 1987 and 1998, 54 (4.4%) developed Krukenberg tumors as a first recurrence without evidence of a distant metastasis. Of these 54 patients, 33 underwent a metastasectomy while 21 did not. The survival duration between the two groups was analyzed and compared. Results. The clinicopathological features of Krukenberg tumors as well as those of the primary cancers in the two groups were similar. All 33 patients in the resection group underwent subsequent adjuvant chemotherapy, including the 7 who received intraperitoneal chemotherapy. The 21 patients in the non-resection group were managed by either systemic chemotherapy (n = 16) or supportive care (n = 5) alone. The median survival duration of all the patients was 9 months (95% confidence interval, 3-15 months). The median survival time in the resection group was 17 months (95% confidence interval, 10-24 months), which was significantly longer than that in the non-resection group, 3 months (95% confidence interval, 2-4 months) (P < 0.001). Conclusion. Our results suggest that a metastasectomy was associated with an improved survival in patients with metachronous Krukenberg tumors from gastric cancer. These data offer a strong argument in favor of performing metastasectomy for Krukenberg tumors in the absence of an obvious distant metastasis.

UR - http://www.scopus.com/inward/record.url?scp=3543123544&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3543123544&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2004.05.007

DO - 10.1016/j.ygyno.2004.05.007

M3 - Article

VL - 94

SP - 477

EP - 482

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 2

ER -